SCHEMBL12436752

SCHEMBL12436752

Nc1ccn(-c2nccs2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 1/20 0.40
NOS1 P29475 1/20 0.40
LMNA P02545 2/20 0.39
GLA P06280 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
POLB P06746 1/20 0.35
APEX1 P27695 1/20 0.35
RECQL P46063 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DAPK3 O43293 1/20 0.35
MAP4K4 O95819 1/20 0.35
PRKACA P17612 1/20 0.35
LTK P29376 1/20 0.35
MAPK8 P45983 1/20 0.35
CSNK1A1 P48729 1/20 0.35
CDK8 P49336 1/20 0.35
CLK2 P49760 1/20 0.35
CDK9 P50750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20758150 0.75 CA12 (0.38) ALDH1A1HSD17B10LMNAGLATDP1
SCHEMBL28308930 0.75 NR3C2 (0.36) ALDH1A1HSD17B10LMNAGLATDP1
SCHEMBL18173879 0.74 NPC1 (0.43) LMNAGLAPOLBMAPTNPC1
SCHEMBL31587061 0.69 AKR1C3 (0.37) ALDH1A1HSD17B10LMNAGLAKDM4E
SCHEMBL5820389 0.69 LMNA (0.42) ALDH1A1HSD17B10TSHRNOS1LMNA
SCHEMBL15638519 0.68 NOS3 (0.39) ALDH1A1NOS1LMNATDP1POLB
SCHEMBL1782525 0.67 ALDH1A1 (0.45) ALDH1A1HSD17B10TSHRNOS1LMNA
SCHEMBL3988944 0.67 LMNA (0.39) ALDH1A1HSD17B10TSHRNOS1LMNA
SCHEMBL20249909 0.67 ALDH1A1 (0.44) ALDH1A1HSD17B10TSHRNOS1TDP1
SCHEMBL30061281 0.67 ALDH1A1 (0.40) ALDH1A1HSD17B10TSHRNOS1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS VERTEX PHARMACEUTICALS INCORPORATED 2018-09-06 US disclosed
WO-2018107056-A1 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-06-14 WO disclosed
WO-2011095997-A1 BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251431-A1 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS HSD17B4, CPT1A, ADH1A ALDH1A1 69/4885HSD17B10 86/4885TSHR 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.